Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical company focused on developing T cell redirecting immunotherapies for cancer treatment, primarily targeting solid tumors. The company operates in the United States and is headquartered in Tübingen, Germany. Its pipeline includes two main modalities: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Key products include Anzu-cel (IMA203), a PRAME-targeted cell therapy in Phase 2 trials, and IMA203CD8, a cell therapy in Phase 1. Additionally, IMA204 targets tumor stroma and is in Phase 1, while TCR Bispecifics like IMA401 and IMA402 are in early clinical development. Immatics also collaborates with MD Anderson Cancer Center, Celgene (now part of Bristol Myers Squibb), and Genmab A/S to advance its therapies.

Immatics N.V. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol IMTX. The company's shares trade in US Dollars (USD). As a foreign private issuer based in Germany, Immatics chose to list on a US exchange to access a broader investor base and benefit from the liquidity of the US capital markets. The NasdaqCM is a market tier of Nasdaq that lists smaller-capitalization companies, providing a platform for emerging growth companies like Immatics to raise capital and increase visibility among investors.

Immatics N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, Immatics focuses on developing innovative therapies that harness the body's immune system to fight cancer. The company's work involves genetic engineering of T cells and the creation of bispecific molecules that redirect T cells to tumor cells. Being in the biotechnology industry means Immatics engages in high-risk, high-reward research and development, with a pipeline of clinical-stage candidates targeting various solid tumors. The sector classification reflects its primary business of using biological processes to create therapeutic products.

Immatics N.V. is headquartered in Tübingen, Germany. While the company is based in Germany, its description indicates that it focuses on the research and development of immunotherapies for the treatment of cancer in the United States. This suggests that the primary market for its clinical trials and potential commercialization is the US, though as a global company, it may also target other regions. The company's strategic collaborations with US-based institutions like MD Anderson Cancer Center and partnerships with US and European firms (Celgene and Genmab) further underscore its focus on the US market. Immatics serves patients with solid tumors through its pipeline of adoptive cell therapies and TCR bispecifics.

Immatics N.V. has a pipeline focused on two treatment modalities: adoptive cell therapies (ACT) and TCR Bispecifics. The lead ACT candidate is Anzu-cel (IMA203), a PRAME-targeted cell therapy currently in Phase 2 trials. Another ACT, IMA203CD8, is in Phase 1. The company also has IMA204, which targets tumor stroma and is in Phase 1. In the TCR Bispecifics category, IMA401 and IMA402 are in Phase 1a clinical trials. Additionally, Immatics is exploring combinations, such as Anzu-cel with Moderna's PRAME cell therapy enhancer (mRNA-4203) in Phase 1. The company has strategic collaborations with MD Anderson Cancer Center, Celgene (now BMS), and Genmab to develop additional therapies targeting multiple cancers.